279 related articles for article (PubMed ID: 34211467)
1. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
Lin J; Zhao S; Wang D; Song Y; Che Y; Yang X; Mao J; Xie F; Long J; Bai Y; Yang X; Zhang L; Bian J; Lu X; Sang X; Pan J; Wang K; Zhao H
Front Immunol; 2021; 12():673248. PubMed ID: 34211467
[TBL] [Abstract][Full Text] [Related]
2. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
[TBL] [Abstract][Full Text] [Related]
4. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
5. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
J Hepatol; 2017 Aug; 67(2):293-301. PubMed ID: 28323123
[TBL] [Abstract][Full Text] [Related]
6. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R
Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003
[TBL] [Abstract][Full Text] [Related]
7. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
8. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
[TBL] [Abstract][Full Text] [Related]
12. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
Jiao J; Sanchez JI; Thompson EJ; Mao X; McCormick JB; Fisher-Hoch SP; Futreal PA; Zhang J; Beretta L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299031
[TBL] [Abstract][Full Text] [Related]
13. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
[TBL] [Abstract][Full Text] [Related]
14. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.
Ikeda S; Tsigelny IF; Skjevik ÅA; Kono Y; Mendler M; Kuo A; Sicklick JK; Heestand G; Banks KC; Talasaz A; Lanman RB; Lippman S; Kurzrock R
Oncologist; 2018 May; 23(5):586-593. PubMed ID: 29487225
[TBL] [Abstract][Full Text] [Related]
15. Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma.
Coto-Llerena M; Benjak A; Gallon J; Meier MA; Boldanova T; Terracciano LM; Ng CKY; Piscuoglio S
JCO Precis Oncol; 2022 Mar; 6():e2100335. PubMed ID: 35263170
[TBL] [Abstract][Full Text] [Related]
16. Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes.
Mezzalira S; De Mattia E; Guardascione M; Dalle Fratte C; Cecchin E; Toffoli G
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694149
[TBL] [Abstract][Full Text] [Related]
17. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA.
Li Z; Xiao D; Li X; Zhan P; Wang J; Zhang H
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):885-892. PubMed ID: 30807446
[TBL] [Abstract][Full Text] [Related]
18. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.
Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
20. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K
J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
